Leerink Partners Upgrades AN2 Therapeutics to Outperform
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has upgraded AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform, as per analyst Joseph Schwartz.
July 05, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners has upgraded AN2 Therapeutics from Market Perform to Outperform, indicating a positive outlook on the stock.
The upgrade from Market Perform to Outperform by a reputable analyst firm like Leerink Partners suggests increased investor confidence and potential for stock price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100